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Abstract Few data have been published regarding the epide-
miology and outcome of infective endocarditis (IE) in patients
with chronic hepatic disease (CHD). A retrospective analysis
of the Studio Endocarditi Italiano (SEI) database was per-
formed to evaluate the epidemiology and outcome of CHD+
patients compared with CHD− patients. The diagnosis of IE
was defined in accordance with the modified Duke criteria.
Echocardiography, diagnosis, and treatment procedures were
in accordance with current clinical practice. Among the 1722
observed episodes of IE, 300 (17.4 %) occurred in CHD+
patients. The cause of CHD mainly consisted of chronic viral
infection. Staphylococcus aureus was the most common bac-
terial species in CHD+ patients; the frequency of other bacte-
rial species (S. epidermidis, streptococci, and enterococci)
were comparable among the two groups. The percentage of
patients undergoing surgery for IE was 38.9 in CHD+ patients
versus 43.7 in CHD− patients (p=0.06). Complications were
more common among CHD+ patients (77 % versus 65.3 %,
p<0.001); embolization (43.3 % versus 26.1 %, p<0.001)
and congestive heart failure (42 % versus 34.1 %, p=0.01)
were more frequent among CHD+ patients. Mortality was
comparable (12.5 % in CHD− and 15 % in CHD+ patients).
At multivariable analysis, factors associated with hospital-
associated mortality were having an infection sustained by
S. aureus, a prosthetic valve, diabetes and a neoplasia, and
CHD. Being an intravenous drug user (IVDU) was a protec-
tive factor and was associated with a reduced death risk. CHD
is a factor worsening the prognosis in patients with IE, in
particular in patients for whom cardiac surgery was required.
Introduction
Progressive changes in classical risk factors and predisposing
conditions for infective endocarditis (IE) have been observed;
IE is increasingly recognized as a healthcare-associated con-
dition often linked with chronic diseases such as renal failure,
diabetes, or cancer [1]. Recently, cirrhosis has been included
among risk factors for IE [2]. An increased risk of bloodstream
infections has been reported in patients with chronic hepatic
disease (CHD), in particular in an advanced form of the dis-
ease [3–5]. Patients with hepatic cirrhosis are at increased risk
for bacteremia following either invasive diagnostics such as
endoscopic variceal ligation, endoscopic sclerotherapy, and
transjugular intrahepatic portosystemic shunts or spontaneous
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events such as variceal bleeding, bacterial peritonitis, and cu-
taneous abrasions in edematous legs [6].
Few data have been published regarding the epidemiology
and outcome of IE in patients with CHD, all in small groups of
patients [7, 8].
A retrospective analysis of the Studio Endocarditi Italiano
(SEI) database was performed to evaluate the epidemiology
and outcome of patients with CHD compared with patients
without CHD.
Methods
Study design
A substudy of IE in patients with or without CHD was per-
formed analyzing the data of the Italian Study on Endocarditis
(SEI) [9], a prospective, observational, multicenter, cohort
study including all consecutive episodes of IE diagnosed from
1st January 2004 through 31st December 2011 at 25 second-
ary and tertiary care institutions. The diagnosis of IE was
defined as possible or definite, in accordance with the modi-
fied Duke criteria [10]. The SEI database was maintained at
the Infectious Diseases Department, Bergamo Hospital. The
study was approved by the ethics committee of this hospital,
and patients consented to enrolment in the SEI cohort as re-
quired by local guidelines and procedures. Echocardiography,
diagnosis, and treatment procedures were in accordance with
current clinical practice (the study did not prescribe a standard
diagnostic and therapeutic approach).
The aim of the substudy was to evaluate the clinical corre-
lations and the outcome of IE in CHD+ patients compared
with CHD− patients. A separate analysis was performed
among CHD+ patients for those who were also intravenous
drug users (CHD+/IVDU+) and those who were not (CHD+/
IVDU−), as each group behaves differently depending on age,
site of infection, and complications.
Clinical data and definitions
Patients were considered CHD+ if a liver disease was reported
in their medical history section of the SEI database. CHD was
classified into four groups: viral related (HCV/HBV/HDV),
alcohol related, autoimmune, or unknown etiology.
Collected information included demography, predisposing
conditions, anatomic site of disease, microbiology, echocar-
diographic findings, antimicrobial and surgical treatment,
complications occurring during the hospitalization (emboliza-
tion, heart failure, death).
The following characteristics were considered as predis-
posing conditions: hemodialysis, diabetes mellitus, current in-
travenous drug abuse, HIV infection, cancer, immunosuppres-
sive therapy, congenital heart disease, native valve
predisposition, previous endocarditis, presence of previously
implanted prosthetic valve.
IE was classified as left-sided (LS-IE), right-sided (RS-IE),
cardiac implantable electronic device associated (CIED-IE),
or prosthetic valve IE.
Infections that occurred 48 h after the hospitalization
were considered as Bhospital acquired^, whereas infec-
tions that occurred in patients who had Brecent and ex-
tensive contact with the healthcare system^, at least in the last
three months before the hospitalization, were considered
Bhealthcare associated^.
Statistical analysis
Categorical variables were described by means of count and
percentage, and quantitative variables by means of median
and interquartile range. The Chi-square test or Fisher’s exact
test, as appropriate, were used in the univariate analyses for
categorical variables, and the Mann–Whitney test was used
for continuum variables. The logistic regression model was
fitted with outcome (dismissed alive or deceased during ad-
mission) as the dependent variable and with infection
sustained by Staphylococcus aureus (yes versus no),
chronic hepatitis (yes versus no), site of infection (LS-
IE versus RS-IE), diabetes (yes versus no), cancer (yes versus
no), preexisting prosthetic valve (yes versus no), and age (for
each year increase) as independent variables. Data are report-
ed as median (IQR 1–3). Analyses were performed using
STATA 13.
Results
Among the 1722 observed episodes of IE (1539 definite
and 183 possible episodes), 300 (17.4 %) occurred in
CHD+ patients. The proportion of patients with a diag-
nosis of possible IE was equally distributed among the
two groups: 11.2 % among CHD− and 8 % among
CHD+ (p= 0.1).
The cause of CHD was chronic viral infection in 241 (213
HCV, 17 HBV, 11 HCV-HBV), alcohol in 35, NASH in six,
primary biliary cirrhosis in one, and unknown in 17 patients.
CHD+ patients were younger and more frequently males than
those who were CHD− (median age 54 versus 64 years,
p<0.001 and males 78.3 % versus 68.3 %, p<0.001, respec-
tively) (Table 1).
The site of infection was statistically different in CHD+
versus CHD− patients, with RS-IE being more common
among CHD+ patients (p<0.001). The data on microbiologic
results are summarized in Table 2. Staphylococcus aureuswas
the most common bacterial species in CHD+ patients,; being
isolated in 92 cases (29.6%), while it was isolated in 261 cases
(18.3 %) among CHD− patients (p<0.0001). The frequency
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of other bacteria species (S. epidermidis, streptococci and en-
terococci) were comparable among the two groups.
Methicillin–resistant S. aureus bacteria were reported in
17.4 % of CHD+ patients and 32.9 % of CHD− patients
(p=0.003). Methicillin-resistant coagulase-negative staphy-
lococci were comparable among the two groups (48 % versus
64.8 % in CHD+ and CHD− patients, respectively, p=0.1).
High-level gentamicin resistance for enterococci was compa-
rable among the two groups (21.4 % versus 25 % CHD+ and
CHD− patients, respectively, p=0.5).
The length of antibiotic treatment was equal for the two
groups (median of 42 days for each group). The proportion
of patients undergoing surgery treatment for IE was 38.9 % in
CHD+ patients versus 43.7 % in CHD− patients (p=0.06); in
particular, a mechanical valve was implanted in 34.8 % versus
31.9 %, bioprosthetic valve in 33.1 % versus 31 %, and
valvuloplasty in 17.4 % versus 11.6 % of CHD+ and CHD−
patients, respectively.
Complications were more common among CHD+ pa-
tients (77 % versus 65.3 %, p < 0.001); embolization
Table 1 Baseline characteristics and complications. Data reported as median (IQR 1–3) or absolute number (%)
Overall,
n= 1739
CHD−,
n = 1428
CHD+,
n= 311
p-Value CHD+/IVDU+,
n= 121
CHD+/IVDU−,
n = 190
p-Value
Demographic data
Age, years 65 (50–74) 67 (55–75) 52 (38–69) <0.001 38 (33–45) 65 (55–74) <0.001
Male sex 1168 (70.1) 933 (68.3) 235 (78.3) <0.001 101 (80.5) 134 (74.6) 0.23
Site of infection
RS-IE 118 59 (4.2) 59 (19.7) 52 (42.3) 7 (4)
LS -IE 1010 845 (59.4) 165 (55) <0.001 58 (46.3) 109 (60) <0.001
CIED-IE 122 109 (7.7) 13 (4.3) 1 (0.8) 12 (6.9)
Prosthetic valve IE 471 408 (28.7) 63 (21) 12 (9.9) 51 (29.1)
Hospital acquired/healthcare associated 646 559 (37.3) 87 (28.1) 0.006 14 (11.2) 73 (39.4) <0.001
Comorbidity and predisposing conditions
Hemodialysis 40 (2.4) 35 (2.56) 5 (1.67) 0.53 2 (1.6) 3 (1.66) NS
Diabetes mellitus 304 (18.24) 259 (18.95) 45 (15) 0.11 4 (2.4) 41 (22.7) <0.001
Current intravenous drug use 148 (8.88) 27 (1.98) 121 (40.33) <0.001 ND ND ND
HIV infection 52 (3.12) 7 (.51) 45 (15) <0.001 38 (30.2) 7 (4.4) <0.001
Cancer 212 (12.72) 176 (12.87) 36 (12) 0.77 3 (3.2) 33 (18.8) <0.001
Immunosuppressive therapy 94 (5.64) 78 (5.71) 16 (5.33) 0.89 1 (0.8) 15 (8.3) 0.004
Congenital heart disease 142 (8.52) 129 (9.44) 13 (4.33) 0.001 5 (4) 8 (4.4) 0.9
Native valve predisposition 414 (24) 365 (25.7) 49 (16.3) 0.001 7 (5.6) 42 (23.8) <0.001
Previous endocarditis 137 (8) 98 (6.9) 39 (13) 0.002 27 (21.4) 12 (7.2) <0.001
Previously implanted prosthetic valve 491 (28.2) 428 (28.8) 63 (20.3) 0.002 12 (9.5) 51 (28.2) <0.001
Therapeutic intervention
Surgery 714 (42.83) 665 (44.8) 121 (38.9) 0.06 42 (33.3) 79 (43.1) 0.2
Mechanical valve 254 (14.1) 212 (31.9) 42 (34.8) 10 (7.9) 32 (17.7)
Bioprosthetic valve 246 (13.7) 206 (31) 40 (33.1) 19 (15.8) 20 (11)
Valvuloplasty 98 (5.5) 77 (11.6) 21 (17.4) 0.08 11 (8.8) 10 (5.5) 0.051
Homograft 29 (1.6) 27 (4.1) 2 (1.7) 1 (0.8) 1 (0.5)
Unknown 159 (8.9) 143 (21.5) 16 (13.2) 1 (0.8) 15 (8.3)
Complications
All complications 1123 (67.4) 886 (65.3) 237 (77) <0.001 102 (81) 135 (74.6) 0.4
Death 238 (12.3) 191 (12.9) 47 (15) 0.3 10 (7.9) 37 (20) 0.004
Embolization 525 (29.2) 391 (26.1) 133 (43.3) <0.001 76 (60.3) 57 (31.5) <0.001
Congestive heart failure 632 (35.5) 499 (33.6) 132 (42) 0.02 42 (49.7) 90 (33.3) 0.06
Site of embolization
CNS 234 (13.) 194 (13.8) 40 (13.4) 0.9 20 (15.9) 23 (12.8) 0.5
Lung 158 (9.3) 98 (7) 60 (20.1) <0.001 50 (39.7) 14 (7.8) <0.001
Abdomen (liver, spleen) 165 (9.7) 127 (9) 38 (12.7) 0.05 13 (10.3) 25 (13.9) 0.5
Bones/muscles 110 (6.4) 91 (6.5) 19 (6.4) 0.9 12 (9.2) 6 (3.3) 0.02
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(43.3 % versus 26.1 %, p< 0.001) and congestive heart
failure (42 % versus 34.1 %, p= 0.01) were more fre-
quent among CHD+ patients. Mortality was comparable
(12.5 % in CHD− patients and 15 % in CHD+ patients)
(Table 3).
Comparison between CHD+/IVDU+ and CHD+/IVDU−
CHD+/IVDU− patients comprised 61 % of CHD+ patients,
were older, and more frequently had concomitant co-
pathologies (i.e., diabetes, cancer) and received immunosup-
pressive therapies than CHD+/IVDU+ patients. In contrast,
CHD+/IVDU+ patients were more frequently HIV positive
(30.2 %).
Regarding cardiac predisposing conditions, CHD+/
IVDU− patients more frequently had a preexisting pros-
thetic valve, while CHD+/IVDU+ patients more fre-
quently had a previous IE episode. The site of infection was
different among the two groups; there were mainly RS-IE for
IVDU+ patients and LS-IE, CIED-IE, or prosthetic valve IE
for IVDU− patients.
Staphylococcus aureus was isolated in 67.8 % of cases of
RS-IE and in 26.7 % of cases of LS-IE. Methicillin resistance
was lower among IVDU+ patients than among IVDU− pa-
tients (10 % versus 34.6 %, p=0.006).
Surgical treatment was not different for the two groups.
Embolization was more common among IVDU+ patients,
while death was more frequently observed among IVDU−
patients. In particular, mortality associated with prosthetic IE
was 23.5 % for IVDU− patients and 8 % for IVDU+ patients.
Among those who underwent surgical treatment, the deceased
comprised 16.6 % of IVDU− patients, compared with 7.8 %
of IVDU+ patients.
Multivariable analysis
At multivariable analysis, factors associated with
hospital-associated mortality were having an infection
sustained by S. aureus, a prosthetic valve, diabetes and
a neoplasia, and CHD. Being an IVDU was a protective
factor and was associated with a reduced death risk
(Table 4).
Table 2 Microbial etiology
Overall,
n= 1739
CHD−,
n= 1428
CHD+,
n= 311
p-Value* CHD+/IVDU+,
n= 121
CHD+/IVDU−,
n= 190
p-Value**
HACEK 4 3 (0.2) 1 (0.3) ns 0 1 (0.5) ns
Staphylococcus aureus 353 261 (18.3) 92 (29.6) <0.0001 64 (50.8) 28 (15.1) <0.0001
Coagulase-negative staphylococci 233 203 (14.2) 30 (9.6) ns 4 (3.2) 26 (14) 0.001
Streptococcus bovis 177 152 (10.6) 25 (8) ns 0 25 (13.5) <0.0001
Streptococcus viridans 267 231 (16.2) 36 (11.6) 0.02 13 (10.3) 23 (12.4) ns
Streptococcus spp. 64 56 (3.9) 8 (2.6) ns 2 (1.6) 6 (3.2) ns
Enterococcus spp. 228 195 (13.7) 33 (10.6) ns 12 (9.5) 21 (11.4) ns
Others 107 94 (6.6) 13 (4.2) ns 4 (3.2) 9 (4.9) ns
Fungi 35 27 (1.9) 8 (2.6) ns 2 (1.6) 6 (3.2) ns
Negative blood culture 315 250 (17.5) 65 (20.9) ns 25 (19.8) 40 21.6) ns
*Comparison between CHD− and CHD+
**Comparison between CHD+/IVDU+ and CHD+/IVDU−
Table 3 Characteristics of deceased patients
Overall,
n= 1739
CHD−,
n= 1428
CHD+,
n= 311
p-Value CHD+/IVDU+,
n= 121
CHD+/IVDU−,
n = 190
p-Value
All deaths 238 (12.3) 191 (12.9) 47 (15) 0.3 10 (7.9) 37 (20) 0.004
Deaths in native valve IE 147 (11.6) 113 (10.7) 34 (13.7) 0.2 9 (7.9) 25 (18.6) 0.01
Deaths in prosthetic valve IE 91 (19.3) 78 (18.2) 13 (20.6) 0.6 1 (8.3) 12 (23.5) 0.2
Deaths in surgically treated IE 67 (9.4) 51 (7.7) 16 (13.2) 0.04 3 (7.1) 13 (16.4) 0.2
Deaths in surgically treated
native valve IE
42 (6.9) 29 (5.8) 13 (12.6) 0.01 3 (7.7) 10 (15.7) 0.4
Deaths in surgically treated
prosthetic valve IE
25 (13.9) 22 (13.6) 3 (16.7) 0.7 0 3 (20) 0.2
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Discussion
The prevalence of CHD (mainly associated with a viral infec-
tion) in the SEI cohort of patients was 17 %. To our knowl-
edge, there are no published data about the prevalence of
chronic hepatitis in patients with endocarditis. However, the
link between CHD and IE is complex and heterogeneous. The
leading role of IVDU is widely recognized, as it is a common
risk factor for both CHD and IE. Among IVDU patients, se-
vere S. aureus infections requiring hospitalization (skin ab-
scesses, cellulitis, septic arthritis, osteomyelitis, and lung ab-
scesses) are frequent [11], and in this group of patients,
S. aureus represents the primary cause of IE.
Moreover, patients with CHD that are not IVDU are at
increased risk for bacteremia, in particular those with ad-
vanced forms of disease [3, 6]. Bacteria isolated from blood
include mainly Gram negative and, with increasing frequen-
cies, also Gram positive [5, 11]. The reasons for the suscepti-
bility to infections associated with bacteremia are different
and include impaired immunity, bacterial translocation, and
clinical factors (i.e., variceal bleeding, spontaneous bacteria
peritonitis, skin lesions) [12]. Healthcare-associated infections
are reported with increasing frequency in this setting; about
15–35 % of patients with liver disease develop nosocomial
infections during their hospital stay as compared with 5–7 %
in the general hospital population [13]. Cirrhosis has been
associated with an increased risk of developing an episode
of IE in a cohort of patients followed for three years [2].
As the two groups, IVDU+ and IVDU−, behave different-
ly, a separate analysis was performed. Among IVDU+ pa-
tients, S. aureus was the leading cause of IE [14, 15]. Major
complications of RS-IE in our group of patients were repre-
sented by septic emboli, particularly to the lungs [14].
Presenting symptoms (such as chest pain, dyspnea, cough,
and hemoptysis, as well as complications of pulmonary
infarction, pulmonary abscess, pneumothorax, pleural effu-
sion, and empyema) result from septic emboli to the lungs.
Mortality in this subgroup was relatively low; in general, mor-
tality associated with IE in addicts is significantly lower than
in non-addicts [16].
Data in the literature about IE in CHD+/IVDU− patients
are limited. A small series was published in 1994, showing a
prevalence of S. aureus infection and a high mortality rate [8].
More recently, Fernández Guerrero et al. [7] reported data
relative to 31 cirrhotic patients with IE; S. aureuswas the most
frequently pathogen isolated. Also, in this last paper, the prog-
nosis of cirrhotic patients was worse than those of the controls,
for the occurrence of acute renal failure and increased surgery-
associated mortality. In the SEI cohort, S. aureus and
coagulase-negative staphylococci (CoNS) were the more fre-
quently isolated bacteria, followed by Streptococcus bovis
(which was fairly uncommon among IVDU+ patients) and,
to a lesser extent, by streptococci and enterococci. The out-
come of LS-IE in CHD+ patients was poor. At multivariable
analysis, CHD positivity was associated with an increased
mortality, while being an IVDU represented a protective
factor. CHD+/IVDU− patients were older and more fre-
quently had a healthcare-associated IE; both factors are
associated with a worse outcome [17]. Cardiac surgery
in patients with hepatic disease may be associated with
an increased number of adverse events and increased
mortality, in particular in advanced forms of hepatic disease
[18]. The perioperative management of a patient with decom-
pensated liver disease is always challenging, and careful pa-
tient selection associated with accurate timing of operation has
been suggested in order to minimize the surgery-associated
mortality [18].
The major limitation of the present study is the absence of
clinical data on the degree of hepatic disease, in particular the
Child–Pugh score. These data could have been helpful in par-
ticular in stratifying the risk of death among patients with
different degrees of hepatic involvement. As a consequence,
the high prevalence of CHD observed in this group of patients
must be interpreted with caution, although CHD is emerging
as a risk factor for IE [2]. Despite this, to our knowledge, the
group reported here is the larger cohort of patients with both
IE and CHD. In summary, our analysis demonstrates that
CHD is a factor worsening the prognosis in patients with IE.
Further studies are needed in this area, and also to evaluate the
relationship between the severity of cirrhosis and IE outcome.
Table 4 Factors associated with
hospital-associated death Univariate analysis Multivariate analysis
IRR p-Value 95 % CI IRR p-Value 95 % CI
Age 1.003 0.02 1.0005–1.006 1.003 0.009 1.0007–1.005
CHD 1.2 0.3 0.85–1.7 1.5 0.04 1.02–2.26
Staphylococcus aureus infection 2.5 <0.0001 1.8–3.4 3 <0.0001 2.2–4.2
Diabetes 1.8 <0.0001 1.4–2.5 1.6 0.007 1.1–2.2
Cancer 1.6 0.006 1.2–2.4 1.9 0.001 1.3–2.7
IVDU 0.7 0.2 0.4–1.2 0.5 0.04 0.3–0.96
Prosthetic valve IE 1.8 <0.0001 1.3–2.4 2 <0.0001 1.5–2.7
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